Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.